AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Previously Presented) A compound of the formula I:



(I)

or a pharmaceutically acceptable salt thereof;

wherein X and Y are independently selected from the group consisting of O, CF_2, CH_2, and CHF;

wherein A is P(O)OH;

R_2 is selected from the group consisting of H, OH, C_1-C_{25} alkyloxy, C_6-C_{10} aryloxy, C_3-C_8 cycloalkyloxy, C_3-C_8 cycloalkyl C_1.C_6 alkoxy, C_2-C_{22} alkenyloxy, C_3-C_8 cycloalkenyloxy, C_7-C_{32} aralkyloxy, C_7-C_{32} alkylaryloxy, C_9-C_{32} aralkenyloxy, and C_9-C_{32} alkenylaryloxy;

R_3-R_6 are independently selected from the group consisting of H and OH; and

R_1 and R_7 are independently selected from the group consisting of C_1-C_{25} alkyl, C_6-C_{10} aryl, C_3-C_8 cycloalkyl, C_2-C_{22} alkenyl, C_3-C_8 cycloalkenyl, C_7-C_{32} aralkyl, C_7-C_{32} alkylaryl, C_9-C_{32} aralkenyl, and C_9-C_{32} alkenylaryl;

with the provisos that (i) when X is O, Y is O or CH_2, and R_3 is H, at least one of R_2 and R_4-R_6 is not OH; (ii) all of R_2-R_6 are not simultaneously H; (iii) R_5 and R_4 are not simultaneously H; (iv) R_2, R_3, R_5, and R_6 are not simultaneously OH or H; and (v) when X and Y are O, R_1 is $C_{18}H_{37}$, and only one of R_2 and R_6 is OCH_3, then R_3 and R_5 are not simultaneously OH.

2. (Canceled)

3. (Currently Amended) The compound ~~or a pharmaceutically acceptable salt~~ of claim 1, which has the formula Ia:



(Ia)

or a pharmaceutically acceptable salt thereof.

4. (Currently Amended) The compound ~~or a pharmaceutically acceptable salt~~ of claim 1, which has the formula Ib:



(Ib)

or a pharmaceutically acceptable salt thereof.

5. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein X and Y are O.

6. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_1 is a C_1-C_{25} alkyl.

7. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_1 is a C_{10}-C_{25} alkyl.

8. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_1 is a C_{15}-C_{20} alkyl.

9. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_1 is a C_{18} alkyl.

10. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_7 is a C_1-C_{25} alkyl.

11. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_7 is a C_1-C_{15} alkyl.

12. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_7 is a C_1-C_5 alkyl.

13. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_7 is methyl.

14. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is C_1-C_{25} alkyloxy.

15. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is C_1-C_{15} alkyloxy.

16. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is C_1-C_5 alkyloxy.

17. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is methoxy.

18. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is C_7-C_{32} aralkyloxy.

19. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is cyclohexylmethoxy.

20. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 is H.

21. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_3 is H.

22. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_4 is H.

23. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_5 is H.

24. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_6 is H.

25. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_2 and R_3 are H.

26. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_3 and R_4 are H.

27. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 1, wherein R_5 and R_6 are H.

28. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 3, wherein X and Y are O, R_1 is $C_{18}H_{37}$, and R_7 is methyl.

29. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 28, wherein R_2 is methoxy, R_3 is H, and R_4-R_6 are OH.

30. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 28, wherein R_2-R_3 are H and R_4-R_6 are OH.

31. (Previously Presented) A compound of the formula:



wherein X and Y are O, R_1 is $C_{18}H_{37}$, and R_7 is methyl; and R_2-R_3 and R_5-R_6 are OH and R_4 is H or a pharmaceutically acceptable salt thereof.

32. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 28, wherein R_2 is i-butyloxy, R_3 is H, and R_4-R_6 are OH.

33. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 28, wherein R_2 is cyclohexylmethoxy, R_3 is H, and R_4-R_6 are OH.

34. (Previously Presented) A compound of the formula:



wherein X and Y are O, R_1 is $C_{18}H_{37}$, R_7 is methyl, R_2-R_3 and R_6 are OH, and R_4-R_5 are H or a pharmaceutically acceptable salt thereof.

35. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 28, wherein R_2-R_4 and R_6 are OH and R_5 is H.

36. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 28, wherein R_2, R_4, and R_6 are OH and R_3 and R_5 are H.

37. (Previously Presented) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable carrier.

38. (Currently Amended) A method of inhibiting activation of the serine/threonine kinase Akt or decreasing phosphorylation in a tumor cell of an animal comprising administering to the animal an effective amount of a compound or a pharmaceutically acceptable salt of claim 1.

39-52. (Canceled)

53. (Currently Amended) A method of increasing apoptosis of a cell comprising contacting the cell with a compound or a pharmaceutically acceptable salt of claim 1.

54. (Currently Amended) A method for inhibiting PH domain binding comprising exposing a material containing an PH domain to a compound or a pharmaceutically acceptable salt of claim 1.

55. (Currently Amended) A method for determining the presence of a PH domain in a material comprising:

(a) exposing a sample of said material to a PH domain binding compound and obtaining a first binding result;
(b) exposing another sample of said material to a compound or a pharmaceutically acceptable salt of claim 1 and obtaining a second binding result; and
(c) comparing the first and second binding results to determine whether a PH domain is present in the material.

56. (Currently Amended) A method of treating cancer in a mammal comprising administering to the mammal an effective amount of a compound or a pharmaceutically acceptable salt of claim 1, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, ovarian cancer, colorectal cancer, and brain cancer.

57. (Canceled)

58. (Previously Presented) A compound of the formula I:



(I)

or a pharmaceutically acceptable salt thereof;
wherein X and Y are independently selected from the group consisting of O, CF_2, CH_2, and CHF;
wherein A is P(O)OH;
R_2 is selected from the group consisting of C_1-C_{25} alkyloxy, cyclohexylmethoxy, and C_7-C_{32} aralkyloxy;
R_3-R_6 are independently selected from the group consisting of H and OH; and
R_1 and R_7 are independently selected from the group consisting of C_1-C_{25} alkyl, C_6-C_{10} aryl, C_3-C_8 cycloalkyl, C_2-C_{22} alkenyl, C_3-C_8 cycloalkenyl, C_7-C_{32} aralkyl, C_7-C_{32} alkylaryl, C_9-C_{32} aralkenyl, and C_9-C_{32} alkenylaryl;
with the provisos that (i) when X is O, Y is O or CH_2, and R_3 is H, at least one of R_2 and R_4-R_6 is not OH; (ii) all of R_2-R_6 are not simultaneously H; and when X and Y are O, R_1 is $C_{18}H_{37}$, and only one of R_2 and R_6 is OCH_3, then R_3 and R_5 are not simultaneously OH.

59. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 58, wherein R_2 is C_1-C_{25} alkyloxy.

60. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 58, wherein R_2 is C_7-C_{32} aralkyloxy.

61. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 58, wherein R_2 is cyclohexylmethoxy.

62. (Previously Presented) The compound or a pharmaceutically acceptable salt of claim 58, wherein R_3 and R_4 are H.

63. (Previously Presented) The compound of claim 58, which has the formula Ia:



(Ia)

wherein X and Y are O, R_1 is $C_{18}H_{37}$, R_7 is methyl, R_2 is methoxy, R_3 is H, and R_4-R_6 are OH or a pharmaceutically acceptable salt thereof.

64. (Currently Amended) A method of increasing apoptosis of a cell comprising contacting the cell with a compound or a pharmaceutically acceptable salt of claim 58.

65. (Currently Amended) A method for inhibiting PH domain binding comprising exposing a material containing an PH domain to a compound or a pharmaceutically acceptable salt of claim 58.

66. (Currently Amended) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of claim 58 and a pharmaceutically acceptable carrier.

67. (Currently Amended) A method of treating cancer in a mammal comprising administering to the mammal an effective amount of a compound or a pharmaceutically

acceptable salt of claim 58, wherein the cancer is selected from the group consisting of lung cancer, breast cancer, ovarian cancer, colorectal cancer, and brain cancer.

68. (Currently Amended) A method of inhibiting activation of the serine/threonine kinase Akt or decreasing phosphorylation in a tumor cell of an animal comprising administering to the animal an effective amount of a compound or a pharmaceutically acceptable salt of claim 58.

69. (Canceled)

70. (Currently Amended) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of claim 31 and a pharmaceutically acceptable carrier.

71. (Currently Amended) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of claim 34 and a pharmaceutically acceptable carrier.